The RV144 trial of a prime-boost vaccine regimen consisting of recombinant canarypox priming immunogen, ALVAC-HIV (vCP1521), and bivalent AIDSVAX®B/E glycoprotein (gp)120 (MN and A244) protein boosting demonstrated a modest 31.2% protective efficacy against HIV infection at 42 months of follow-up; however, vaccine efficacy was 60.5% at 12 months after initial vaccination [14, 15]. The gene discussed is ITIH4; the disease is HIV infectious disease.